• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

变异阴性会是高级别浆液性卵巢癌吗？病例系列报告

Can variant negative be high-grade serous ovarian carcinoma? A case series.

作者信息

Kasherman Lawrence, Garg Swati, Tchrakian Nairi, Clarke Blaise, Karakasis Katherine, Kim Raymond H, Stockley Tracy L, Dhani Neesha, Oza Amit M, Lheureux Stephanie

机构信息

Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

出版信息

Gynecol Oncol Rep. 2021 Feb 12;36:100729. doi: 10.1016/j.gore.2021.100729. eCollection 2021 May.

DOI:10.1016/j.gore.2021.100729
PMID:33718561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7910505/
Abstract

• variant negative high-grade serous ovarian cancer is rare and can still show p53 abnormal immunohistochemistry.•Diagnostic and therapeutic considerations include pathologic, molecular and clinical domains.•Genetic reassessment through more comprehensive assays should be considered to ensure no missed rare or complex variants.•Presence of mutations can occur in variant high-grade serous ovarian cancer.

摘要

• 变异阴性的高级别浆液性卵巢癌很罕见，但仍可显示p53免疫组化异常。

• 诊断和治疗考量包括病理学、分子学和临床领域。

• 应考虑通过更全面的检测进行基因重新评估，以确保不遗漏罕见或复杂变异。

• 变异型高级别浆液性卵巢癌中可出现突变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/2b11a78a4c61/fx2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/21c83cd00f7e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/3cdebea141d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/eff67ecdd8e6/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/c6a8a1e60423/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/2b11a78a4c61/fx2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/21c83cd00f7e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/3cdebea141d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/eff67ecdd8e6/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/c6a8a1e60423/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605c/7910505/2b11a78a4c61/fx2.jpg

相似文献

1
Can variant negative be high-grade serous ovarian carcinoma? A case series.变异阴性会是高级别浆液性卵巢癌吗？病例系列报告
Gynecol Oncol Rep. 2021 Feb 12;36:100729. doi: 10.1016/j.gore.2021.100729. eCollection 2021 May.
2
Targeted Genomic Sequencing Reveals Novel In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.靶向基因组测序揭示导致高级别浆液性输卵管卵巢癌中p53过表达的新型框内缺失突变。
Anticancer Res. 2019 Jun;39(6):2883-2889. doi: 10.21873/anticanres.13417.
3
High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.伴有黏液样分化的高级别浆液性卵巢癌：1例罕见且独特病例报告，提示从高级别浆液性癌的“SET”特征向“STEM”特征转变
Diagn Pathol. 2019 Jan 12;14(1):4. doi: 10.1186/s13000-019-0781-9.
4
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.TP53的分子改变是卵巢高级别浆液性癌的一个决定性特征：对癌症基因组图谱卵巢研究中缺乏TP53突变病例的重新审视。
Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.
5
Identification of Novel Somatic Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).采用下一代测序（NGS）技术鉴定高级别浆液性卵巢癌（HGSOC）患者的新型体细胞突变。
Int J Mol Sci. 2018 May 18;19(5):1510. doi: 10.3390/ijms19051510.
6
Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.采用多基因二代测序癌症检测板方法对浆液性卵巢癌进行分子特征分析。
BMC Res Notes. 2014 Nov 17;7:805. doi: 10.1186/1756-0500-7-805.
7
Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.卵巢浆液性癌伴高级别和低级别浆液性癌混合形态学特征的临床病理、免疫组织化学和分子特征。
Am J Surg Pathol. 2020 Mar;44(3):316-328. doi: 10.1097/PAS.0000000000001419.
8
Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.同源重组修复相关基因体细胞变异对卵巢高级别浆液性癌的临床影响。
Cancer Res Treat. 2020 Apr;52(2):634-644. doi: 10.4143/crt.2019.207. Epub 2020 Jan 6.
9
Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.p53 免疫染色模式为野生型的卵巢输卵管腹膜高级别浆液性癌的靶向测序。
In Vivo. 2019 Sep-Oct;33(5):1485-1492. doi: 10.21873/invivo.11628.
10
Spectrum of Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer.与BRCA1/2相关的高级别浆液性卵巢癌中的突变谱
Front Oncol. 2020 Jul 16;10:1103. doi: 10.3389/fonc.2020.01103. eCollection 2020.

引用本文的文献

1
Isolated low-grade serous carcinoma arising in inguinal lymph nodes in the setting of endosalpingiosis: A case report.输卵管内膜异位症背景下腹股沟淋巴结出现的孤立性低级别浆液性癌：一例报告
Gynecol Oncol Rep. 2025 May 23;59:101769. doi: 10.1016/j.gore.2025.101769. eCollection 2025 Jun.
2
Deciphering cancer genomes with GenomeSpy: a grammar-based visualization toolkit.使用 GenomeSpy 破解癌症基因组：基于语法的可视化工具包。
Gigascience. 2024 Jan 2;13. doi: 10.1093/gigascience/giae040.

本文引用的文献

1
Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.TP53 野生型卵巢输卵管高级别浆液性癌的特征：卵巢浆液性癌二元分类法的罕见例外。
Mod Pathol. 2021 Feb;34(2):490-501. doi: 10.1038/s41379-020-00648-y. Epub 2020 Aug 15.
2
Spectrum of Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer.与BRCA1/2相关的高级别浆液性卵巢癌中的突变谱
Front Oncol. 2020 Jul 16;10:1103. doi: 10.3389/fonc.2020.01103. eCollection 2020.
3
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive -mutant Ovarian Cancer.
贝伐珠单抗联合紫杉醇和卡铂治疗铂敏感复发性卵巢癌的 II 期随机临床试验 **解析**：英文文本的主语为“A Biomarker-enriched, Randomized Phase II Trial”，翻译为中文时为了使译文更符合中文表达习惯，调整了语序，译为“贝伐珠单抗联合紫杉醇和卡铂治疗铂敏感复发性卵巢癌的 II 期随机临床试验”。
Clin Cancer Res. 2020 Sep 15;26(18):4767-4776. doi: 10.1158/1078-0432.CCR-20-0219. Epub 2020 Jul 1.
4
Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.输卵管和卵巢表面上皮都是高级别浆液性卵巢癌的起源细胞。
Nat Commun. 2019 Nov 26;10(1):5367. doi: 10.1038/s41467-019-13116-2.
5
Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice.肿瘤组织的匹配全基因组测序（WGS）和全外显子组测序（WES）与循环肿瘤DNA（ctDNA）分析：临床实践中的互补模式
Cancers (Basel). 2019 Sep 19;11(9):1399. doi: 10.3390/cancers11091399.
6
Intratumour heterogeneity of p53 expression; causes and consequences.肿瘤内 p53 表达异质性；原因和后果。
J Pathol. 2019 Nov;249(3):274-285. doi: 10.1002/path.5328. Epub 2019 Aug 27.
7
TP53 mutations in epithelial ovarian cancer.上皮性卵巢癌中的TP53突变
Transl Cancer Res. 2016 Dec;5(6):650-663. doi: 10.21037/tcr.2016.08.40.
8
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.口服 ENMD-2076 治疗卵巢透明细胞癌的临床和分子 II 期试验：玛格丽特公主癌症中心 II 期联盟研究。
Clin Cancer Res. 2018 Dec 15;24(24):6168-6174. doi: 10.1158/1078-0432.CCR-18-1244. Epub 2018 Aug 14.
9
Ovarian cancer statistics, 2018.卵巢癌统计数据，2018 年。
CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
10
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.全基因组和高密度 CRISPR-Cas9 筛选鉴定出导致 PARP 抑制剂耐药性的 PARP1 点突变。
Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2.